Txog-mob cancer / kho mob / kuaj mob-sim / mob / mos-nqaij mos-sarcoma / kho mob
Kev Kho Mob Soj Ntsuam Sim Rau Cov Mos Mos Sarcoma
Cov chaw kuaj mob yog cov kev tshawb fawb tshawb fawb uas cuam tshuam nrog tib neeg. Kev kuaj mob hauv cov npe no yog rau kev kho tus mob sarcoma nqaij mos. Txhua qhov kev sim ntawm daim npe tau txhawb los ntawm NCI.
NCI cov ncauj lus tseem ceeb txog kev sim kho mob piav qhia txog ntau hom thiab ncua sij hawm ntawm kev sim thiab seb lawv raug coj los ua li cas. Cov chaw soj ntsuam kuaj xyuas txoj hauv kev tshiab los tiv thaiv, kuaj pom, lossis kho kab mob. Tej zaum koj yuav xav xav txog kev koom tes hauv kev sim tshuaj kuaj mob. Tham nrog koj tus kws kho mob kom pab txiav txim siab yog tias ib qho zoo rau koj.
Erdafitinib hauv Kev Kho Mob Rau Cov Neeg Mob Nrog Relapsed lossis Refractory Advanced Solid Tumors, Tsis-Hodgkin Lymphoma, lossis Keeb Kwm Kev Mob Siab nrog FGFR Kev Hloov (Ib Txoj Kev Kho Mob MATCH Kev Kho Mob)
Theem II Pediatric MATCH txoj kev kawm no qhia tau hais tias cov neeg mob hlwb ua haujlwm zoo npaum li cas rau kev kho cov neeg mob qog ua pob, tsis mob Hodgkin lymphoma, lossis keeb kwm mob uas kis mus rau lwm qhov chaw hauv lub cev thiab tau rov qab los yog tsis teb rau kev kho mob nrog FGFR kev hloov pauv. Erdafitinib tuaj yeem nres kev loj hlob ntawm cov qog nqaij hlav ntshav los ntawm kev thaiv qee cov enzymes xav tau rau kev loj hlob ntawm tes.
Qhov chaw nyob: 107 chaw
Tazemetostat hauv Kev Kho Cov Neeg Mob Nrog Relapsed lossis Refractory Advanced Khoom Qog Pob Qij, Tsis-Hodgkin Lymphoma, lossis Keeb Kwm Kev Mob Hlwb nrog EZH2, SMARCB1, lossis SMARCA4 Gene Mutations (Ib Txoj Kev Kho Mob Kuaj Mob Me Me)
Theem II Pediatric MATCH kev tshawb fawb txog kev kho mob tazemetostat ua haujlwm zoo li cas rau kev kho cov neeg mob qog ua pob, tsis mob hodgkin lymphoma, lossis keeb kwm tsis zoo uas tau kis mus rau lwm qhov chaw hauv lub cev thiab tau rov qab los yog tsis teb rau kev kho mob thiab muaj EZH2, SMARCB1 , lossis SMARCA4 noob hloov pauv. Tazemetostat tuaj yeem tso tseg txoj kev loj hlob ntawm cov qog hlwb los ntawm kev thaiv qee cov enzymes xav tau rau kev loj hlob ntawm tes.
Qhov chaw: 109 thaj chaw
PI3K / mTOR Tus Neeg Kho Mob LY3023414 hauv Kev Kho Mob Rau Cov Neeg Mob Nrog Rov Kho Mob lossis Kho Kom Zoo Dua Cov Qog Pob Qij, Tsis-Hodgkin Lymphoma, lossis Histiocytic Tsis sib haum nrog TSC lossis PI3K / MTOR Ob Txoj Kev Hloov (Kev Tshuaj Ntsuam MATCH Kev Kho Mob)
Theem II Pediatric MATCH kev tshawb nrhiav seb qhov PI3K / mTOR inhibitor LY3023414 ua haujlwm zoo npaum li cas rau kev kho cov neeg mob qog, tsis mob Hodgkin lymphoma, lossis keeb kwm tsis zoo nrog TSC lossis PI3K / MTOR kev hloov pauv uas tau kis mus rau lwm qhov chaw hauv lub cev (metastatic) thiab tau rov qab los (rov qab ua dua) lossis tsis teb rau kev kho mob (refractory). PI3K / mTOR inhibitor LY3023414 tuaj yeem tso tseg txoj kev loj hlob ntawm qog nqaij hlav ntshav los ntawm kev thaiv qee cov enzymes xav tau rau kev loj hlob ntawm tes.
Qhov chaw nyob: 107 chaw
Palbociclib hauv Kev Kho Mob Rau Cov Neeg Mob Nrog Relapsed lossis Refractory Rb Zoo Tshaj Tawv Nrov Qog, Tsis-Hodgkin Lymphoma, lossis Keeb Kwm Kev Mob Loj nrog kev ua kom muaj kev hloov pauv hauv Cov Neeg Keeb Kwm Ntawm Lub Hlwb
Theem II Pediatric MATCH cov kev tshawb fawb pom zoo npaum li cas palbociclib ua haujlwm hauv kev kho cov neeg mob nrog cov hlav qog ua tau zoo, tsis muaj mob Hodgkin lymphoma, lossis keeb kwm tsis zoo nrog kev ua kom muaj kev hloov (hloov mus) hauv cov keeb kwm ntawm tes uas tau kis mus rau lwm qhov chaw hauv lub cev thiab tau tuaj rov qab lossis tsis teb rau kev kho mob. Palbociclib tuaj yeem nres kev loj hlob ntawm cov qog nqaij hlav ntshav los ntawm kev thaiv qee cov enzymes xav tau rau kev loj hlob ntawm tes.
Qhov chaw: 97 thaj chaw
Larotrectinib hauv Kev Kho Tus Neeg Mob Nrog Relapsed lossis Refractory Advanced Khoom Qog Pob Qij, Tsis-Hodgkin Lymphoma, lossis Keeb Kwm Kev Mob Hlwb nrog NTRK Fusions (Ib Txoj Kev Kho Mob MATCH Kev Kho Mob)
Theem II Pediatric MATCH cov kev tshawb fawb pom zoo npaum li cas larotrectinib ua haujlwm hauv kev kho cov neeg mob qog ua pob, tsis mob Hodgkin lymphoma, lossis keeb kwm tsis zoo nrog NTRK fusions uas tau kis mus rau lwm qhov chaw hauv lub cev thiab tau rov qab los yog tsis teb rau kev kho mob. Larotrectinib tuaj yeem nres kev loj hlob ntawm cov qog nqaij hlav ntshav los ntawm kev thaiv qee cov enzymes uas xav tau rau kev loj hlob ntawm tes.
Qhov chaw: 109 thaj chaw
Cabozantinib-S-Malate hauv Kev Kho Cov Neeg Mob Hluas Dua nrog Kev Rov Qab Rov Qab, Refractory, lossis Tshiab Txoj Kev Kho Mob Sarcomas, Wilms Tumor, lossis Lwm Yam Khoom Ua Rog Loj
Kev sim qib II no kawm paub hais tias cabozantinib-s-malate ua haujlwm zoo npaum li cas rau kev kho cov neeg mob hluas uas muaj mob sarcomas, Wilms hlav, lossis lwm cov qog uas tsis tshua muaj mob uas tau rov qab los, tsis teb rau txoj kev kho, lossis nyuam qhuav raug kuaj mob tshiab. Cabozantinib-s-malate tuaj yeem txwv txoj kev loj hlob ntawm cov qog cov qog los ntawm kev thaiv qee cov enzymes xav tau rau kev loj hlob qog thiab cov qog cov ntshav cov ntshav.
Qhov chaw: 137 thaj chaw
Olaparib hauv Kev Kho Cov Neeg Mob Nrog Relapsed lossis Refractory Advanced Solid Tumors, Tsis-Hodgkin Lymphoma, lossis Histiocytic Tsis sib haum nrog kev tsis zoo hauv DNA Puas Kho Cov Qib (Cov Kev Kho Mob Kuaj Mob Me Nyuam)
Theem II Pediatric MATCH cov kev tshawb fawb pom zoo npaum li cas olaparib ua haujlwm hauv kev kho cov neeg mob qog ua pob zeb, tsis yog Hodgkin lymphoma, lossis keeb kwm mob tsis txaus nrog kev kho cov kab mob deoxyribonucleic acid (DNA) kev puas tsuaj kho cov noob uas tau kis mus rau lwm qhov chaw hauv lub cev (advanced) thiab tau rov qab los (rov ua haujlwm dua) lossis tsis teb rau kev kho mob (refractory). Olaparib yuav nres qhov kev loj hlob ntawm cov qog ntshav los ntawm kev thaiv qee cov enzymes xav tau rau kev loj hlob ntawm tes.
Qhov chaw: 105 thaj chaw
Vemurafenib hauv Kev Kho Mob Rau Cov Neeg Mob Nrog Relapsed lossis Refractory Advanced Khoom Qog Pob Qij, Tsis-Hodgkin Lymphoma, lossis Keeb Kwm Kev Mob Hlav nrog BRAF V600 Kev Sib Hloov (Kev Kho Mob MATCH Txoj Kev Kho Mob)
Theem II Pediatric MATCH cov kev tshawb fawb pom tias vemurafenib ua haujlwm zoo npaum li cas rau kev kho cov neeg mob qog ua pob, tsis mob Hodgkin lymphoma, lossis keeb kwm tsis zoo nrog BRAF V600 hloov uas kis mus rau lwm qhov chaw hauv lub cev thiab tau rov qab los yog tsis teb kev kho mob. Vemurafenib tuaj yeem nres kev loj hlob ntawm cov qog ntshav los ntawm kev thaiv qee cov enzymes xav tau rau kev loj hlob ntawm tes.
Qhov chaw: 106 thaj chaw
Atezolizumab hauv Kev Kho Mob rau Cov Neeg Mob Nrog Kev Tshuaj Ntsig Tshiab thiab Metastatic Alveolar Muag Qhov Muag Sarcoma Uas Tshem Tawm Tsis Tau
Kev sim qib II no kawm txog kev noj cov zaub mov zoo li cas ua rau cov neeg mob alveolar mos sarcoma tsis tau kho, tau kis los ntawm qhov chaw nws pib rau lwm qhov chaw hauv lub cev thiab tsis tuaj yeem raug tshem tawm los ntawm kev phais mob. Kev txhaj tshuaj tiv thaiv kab mob nrog monoclonal tiv thaiv kab mob, xws li Eatzolizumab, tuaj yeem pab lub cev tiv thaiv kab mob ntawm lub cev tua cov kabmob, thiab yuav cuam tshuam lub peev xwm ntawm cov qog ua kom loj hlob thiab kis tau.
Qhov chaw: 39 thaj chaw
Nivolumab thiab Ipilimumab hauv Kev Kho Cov Neeg Mob Nrog Tus Mob HIV Tus Mob Hnyav Qav Rov Qab lossis Lub Pob Qij Pob Qog Hodgkin Lymphoma lossis Lub Pob Ntsej Cov Khoom Uas Muaj Tsuag
Qeb ib theem no kuv sim kawm txog cov kev mob tshwm sim thiab qhov zoo tshaj plaws ntawm nivolumab thaum muab nrog ipilimumab rau kev kho cov neeg mob tib neeg cov tshuaj tiv thaiv kab mob (HIV) cuam tshuam los ntawm Hodgkin lymphoma uas tau rov qab los tom qab lub sijhawm txhim kho lossis tsis teb rau kev kho mob, lossis cov qog tawv uas tau kis mus rau lwm qhov chaw hauv lub cev lossis tsis tuaj yeem raug tshem tawm los ntawm kev phais mob. Kev txhaj tshuaj tiv thaiv kab mob nrog monoclonal tiv thaiv kab mob, xws li ipilimumab thiab nivolumab, tuaj yeem pab lub cev tiv thaiv kab mob tua cov kab mob qog nqaij hlav, thiab yuav cuam tshuam lub peev xwm ntawm cov qog ntshav kom loj hlob thiab kis tau. Ipilimumab yog cov tshuaj tiv thaiv uas ua tawm tsam ib qho qauv hu ua cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 tswj ib feem ntawm koj lub cev tiv thaiv kab mob los ntawm kev kaw cia. Nivolumab yog ib hom tshuaj tiv thaiv kab mob uas muaj tshwj xeeb rau tib neeg cov kab mob cell tuag 1 (PD-1), ib qho protein ua lub luag haujlwm rau kev rhuav tshem cov kab mob tiv thaiv kab mob. Muab cov tshuaj ipilimumab nrog nivolumab tuaj yeem ua haujlwm zoo dua rau kev kho cov neeg mob HIV nrog Hodgkin lymphoma lossis cov qog ua haujlwm piv rau ipilimumab nrog nivolumab ib leeg.
Qhov chaw: 28 thaj chaw
MDM2 Tus Kws Lij Choj AMG-232 thiab Kev Xaj Txau Hluav Taws Xob hauv Kev Kho Mob rau Cov Neeg Mob Mos Mos Mos Cov nqaij mos Sarcoma
Theem Ib ntu no kawm txog kev phiv los ntawm MDM2 inhibitor AMG-232 thiab kev kho hluav taws xob hauv kev kho mob rau cov neeg mob mos mos sarcoma. MDM2 inhibitor AMG-232 tuaj yeem nres kev loj hlob ntawm cov qog nqaij hlav cancer los ntawm kev thaiv qee cov enzymes xav tau rau kev loj hlob ntawm tes. Muab MDM2 inhibitor AMG-232 thiab hluav taws xob kev kho mob ua ntej kev phais mob yuav ua rau cov qog ntshav me dua thiab txo cov nqaij mos uas yuav tsum tau tshem tawm.
Qhov chaw: 27 thaj chaw
Nivolumab nrog lossis tsis siv Ipilimumab hauv Kev Kho Cov Neeg Mob Hluas Dua nrog Mob Rov Ntshav Rov Qab lossis Cov Pob Qij Tawv Los yog Sarcomas
Theem I / II kev sim no kawm txog cov kev mob tshwm sim thiab qhov zoo tshaj plaws ntawm nivolumab thaum muab nrog lossis tsis muaj ipilimumab kom pom tias lawv ua haujlwm zoo npaum li cas rau kev kho cov neeg mob qog nqaij hlav tawv lossis tawv nqaij uas rov qab tshwm sim (ib qho dua) lossis tsis teb rau kev kho refractory). Kev txhaj tshuaj tiv thaiv kab mob nrog monoclonal tiv thaiv kab mob, xws li nivolumab thiab ipilimumab, tuaj yeem pab lub cev tiv thaiv kab mob tua lub qog ntshav, thiab yuav cuam tshuam lub peev xwm ntawm cov qog ntshav kom loj hlob thiab kis tau. Nws tseem tsis tau paub meej tias nivolumab ua haujlwm zoo dua nyob ib leeg lossis nrog ipilimumab hauv kev kho cov neeg mob uas rov ua dua li lossis cov nqaij hlav tawv lossis cov pob zeb tawv.
Qhov chaw: 24 thaj chaw
Selinexor hauv Advanced Liposarcoma
Qhov no yog kev xaiv ntau, multicenter, ob lub qhov muag dig, tshuaj placebo-tswj, Theem 2-3 kev tshawb fawb ntawm cov neeg mob kuaj mob siab kawg tsis tuaj yeem txiav tawm liposarcoma. Kwv yees li 279 tus neeg mob tag nrho yuav raug xaiv kawm kev kho (selinexor lossis placebo).
Qhov chaw: 21 thaj chaw
(VOYAGER) Kev Tshawb Fawb ntawm Avapritinib vs Regorafenib hauv Kev Mob Rau Cov Neeg Mob Nrog Kev Siv Hauv Cheeb Tsam Tsis paub tab lossis Metastatic GIST
Qhov no yog qhib-daim ntawv lo cim, xaiv, ntu 3 kawm nyob hauv cov neeg mob uas tsis muaj kev tiv thaiv lossis thaj tsam Gist (GIST) siab ntawm avapritinib (tseem hu ua BLU-285) tiv thaiv regorafenib hauv cov neeg mob yav tas los kho nrog imatinib thiab 1 lossis 2 lwm TKI.
Qhov chaw: 14 thaj chaw
Ib Theem 1 Txoj Kev Tshawb Fawb ntawm EZH2 Tus Tuav Cov Tazemetostat hauv Cov Neeg Lom Zem Nrog Cov Khoom So Rov Los lossis Refractory INI1-Tsis Caj Qoob Ntxiv lossis Synovial Sarcoma
Qhov no yog Ntu I, qhib-daim ntawv lo, koob tshuaj nce ntxiv thiab koob tshuaj nthuav dav nrog qhov BID qhov ncauj ntawm tazemetostat. Cov ntsiab lus yuav raug kuaj seb puas tsim nyog nyob rau hauv 14 hnub ntawm thawj koob tshuaj tazemetostat. Lub sijhawm kho yuav yog 28 hnub. Cov lus teb kev soj ntsuam yuav raug soj ntsuam tom qab 8 lub lis piam ntawm kev kho mob thiab tom qab ntawd txhua 8 lub lis piam thaum tab tom tshawb fawb. Txoj kev tshawb no muaj ob ntu: Kev Tsiv Npaum thiab Kev Tshawb Fawb. Koob nce toj siab rau cov ncauj lus nrog cov mob rov qab ua dua qub / rov mob dua ntxiv: - Cov qog mob hauv lub cev: - Cov qog mob uas mob ua kom mob raumdoid mob (ATRT) - qog mob malignant rhabdoid (MRT) - Cov qog Rhabdoid lub raum (RTK) - Cov qog uas xaiv :
Qhov chaw: 14 thaj chaw
Adavosertib thiab Irinotecan Hydrochloride hauv Kev Kho Cov Neeg Mob Hluas Dua nrog Cov Mob Qog Rov Qab lossis Cov Pob Qij Taub
Theem I / II kev sim no kawm txog cov kev mob tshwm sim thiab qhov zoo tshaj plaws ntawm adavosertib thiab irinotecan hydrochloride hauv kev kho cov neeg mob uas muaj cov qog laus uas tau rov qab los (rov mob dua) lossis uas tsis tau teb rau tus qauv kev kho (refractory). Adavosertib thiab irinotecan hydrochloride tuaj yeem nres kev loj hlob ntawm cov qog ntshav los ntawm kev thaiv qee cov enzymes uas xav tau rau kev loj hlob ntawm tes.
Qhov chaw: 22 thaj chaw
Lub Ntse III Kev sim ntawm Anlotinib hauv Metastatic lossis Advanced Alveolar Mos Tshooj Sarcoma, Leiomyosarcoma thiab Synovial Sarcoma
Txoj kev tshawb no soj ntsuam kev nyab xeeb thiab ua tau zoo ntawm AL3818 (anlotinib) hydrochloride hauv kev kho mob ntawm metastatic lossis advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), thiab synovial sarcoma (SS). Txhua tus neeg koom nrog ASPS yuav tau txais daim ntawv qhib AL3818. Hauv cov neeg koom nrog LMS lossis SS, AL3818 yuav piv rau IV dacarbazine. Ob feem peb ntawm cov neeg koom yuav tau txais AL3818, ib feem peb ntawm cov neeg koom yuav tau txais IV dacarbazine.
Qhov chaw: 14 thaj chaw
Nab-Paclitaxel thiab Gemcitabine Hydrochloride hauv Kev Kho Cov Hluas lossis Cov Hluas Thaum Hluas nrog Kev Rov Ntsuam Dua lossis Refractory Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, lossis Mos Nqaij Sarcoma
Kev sim qib II no kawm paub seb nab-paclitaxel thiab gemcitabine hydrochloride ua haujlwm rau kev kho cov hluas lossis cov neeg hluas nrog cov txha caj qaum, Ewing sarcoma, rhabdomyosarcoma, lossis cov nqaij mos sarcoma uas tau rov qab los yog tsis teb rau kev kho mob. Cov tshuaj siv hauv kev siv tshuaj kho mob, xws li nab-paclitaxel thiab gemcitabine hydrochloride ua haujlwm nyob rau ntau txoj hauv kev los tiv thaiv kev loj hlob ntawm cov qog hlwb, los ntawm kev tua cov qog, los ntawm kev txwv kom tsis txhob faib tawm, lossis los ntawm txwv tsis pub kis mus rau.
Qhov chaw: 18 thaj chaw
Olaparib thiab Temozolomide hauv Kev Kho Mob rau Cov Neeg Mob Nrog Kev Tshaj Lij, Metastatic, lossis Kev Siv Tsis Tau Uterine Leiomyosarcoma
Kev sim qib II no kawm txog olaparib thiab temozolomide hauv kev kho cov neeg mob uterine leiomyosarcoma (LMS) uas tau kis mus rau lwm qhov chaw hauv lub cev (qib siab lossis metastatic) lossis tsis tuaj yeem raug tshem tawm los ntawm kev phais mob (tsis siv neeg). Olaparib yuav nres qhov kev loj hlob ntawm cov qog ntshav los ntawm kev thaiv qee cov enzymes xav tau rau kev loj hlob ntawm tes. Cov tshuaj siv hauv kev siv tshuaj kho mob, xws li temozolomide ua haujlwm nyob rau ntau txoj hauv kev los tiv thaiv kev loj hlob ntawm cov qog nqaij hlav, los ntawm tua cov hlwb, los ntawm kev txwv lawv kom faib, lossis txwv tsis pub kis mus rau lwm qhov. Kev muab olaparib thiab temozolomide tuaj yeem ua haujlwm zoo dua li muab cov tshuaj ib leeg rau hauv kev kho cov neeg mob LMS.
Qhov chaw: 12 thaj chaw
Kev Nyab Xeeb Kev Nyab Xeeb, Kev Ncaj Ncees thiab PK Kev Kawm ntawm DCC-2618 hauv Cov Neeg Mob Nrog Kev Tshaj Tawm Malignancies
Qhov no yog Ntu 1, qhib-daim ntawv lo, thawj-hauv-tib neeg (FIH) koob tshuaj-kev kawm nce siab los tsim kev tshuaj xyuas txog kev nyab xeeb, kev tiv taus zoo, cov tshuaj pharmacokinetics (PK), pharmacodynamics (PD) thiab kev tiv thaiv ua ntej ntawm kev ua haujlwm ntawm DCC-2618, tswj hwm qhov ncauj (PO), hauv cov neeg laus cov neeg mob uas muaj lub siab phem. Txoj kev tshawb fawb muaj 2 ntu, ntu-nce-nce qib thiab qhov kev nthuav dav.
Qhov chaw: 12 thaj chaw
Nelfinavir Mesylate hauv Kev Kho Mob rau Cov Neeg Mob nrog Kaposi Sarcoma
Qhov kev sim theem II no tshawb txog seb qhov mob nelfinavir mesylate ua haujlwm zoo li cas rau kev kho cov neeg mob Kaposi sarcoma. Nelfinavir mesylate tuaj yeem nres kev loj hlob ntawm cov qog ntshav los ntawm kev thaiv qee cov enzymes xav tau rau kev loj hlob ntawm tes.
Qhov chaw: 11 thaj chaw
sEphB4-HSA hauv Kev Kho Cov Neeg Mob nrog Kaposi Sarcoma
Kev tshawb nrhiav qib II no xav rov kho dua EphB4-HSA fusion protein (sEphB4-HSA) hauv kev kho cov neeg mob Kaposi sarcoma. Recombinant EphB4-HSA fusion protein tuaj yeem thaiv kev loj hlob ntawm cov hlab ntsha uas muab ntshav rau cov qog nqaij hlav, thiab tseem tuaj yeem tiv thaiv qog noj ntshav tsis tuaj yeem loj hlob tuaj.
Qhov chaw: 10 thaj chaw
Ib Ntu II, Ntau Txoj Kev Tshawb Fawb ntawm EZH2 Tus Tuav Cov Tazemetostat hauv Cov Neeg Laus Hauv Qhov Tsis Txaus Nrog INI1-Cov Tawv Qog Tsis Zoo lossis Rov Tsuag Dua / Refractory Synovial Sarcoma
Qhov no yog Ntu II, multicenter, qhib-daim ntawv lo, ib txhais caj npab, 2-theem kev kawm ntawm tazemetostat 800 mg BID muab qhov ncauj rau hauv 28 hnub mus ncig. Kev soj ntsuam ntawm cov ncauj lus los txiav txim siab tsim nyog rau txoj kev tshawb no yuav ua tiav tsis pub dhau 21 hnub ntawm thawj zaug tau teem tseg ntawm tazemetostat. Cov muaj cai kawm yuav raug cuv npe mus rau ib ntawm tsibcohorts raws li hom qog: - Cohort 1 (Kaw rau kev tso npe nkag): MRT, RTK, ATRT, lossis xaiv cov qog uas muaj cov yam ntxwv rhabdoid, suav nrog cov cell me me carcinoma ntawm ovary hypercalcemic type [SCCOHT], kuj tseem paub tias mob rhaboid mob qog ntawm lub zes qe menyuam [MRTO] - Cohort 2 (Kaw rau kev sau npe kawm): Cov mob tshwm sim lossis rov ua haujlwm nrog tus mob SS18-SSX kho dua tshiab - Cohort 3 (Kaw rau kev sau npe kawm): Lwm yam kev mob qog tsis zoo lossis lub qog ua pob nrog EZH2 nce ntawm kev ua haujlwm (GOF) kev hloov pauv, suav nrog:
Qhov chaw: 12 thaj chaw
SARC024: Daim Ntawv Cog Lus Tseg rau Txoj Kev Tshawb Fawb Kev Tshawb Fawb Txog Qhov Ncauj Hauv Cov Neeg Mob Nrog Xaiv Sarcoma Subtypes
Txawm hais tias regorafenib tau txais kev pom zoo rau kev siv rau cov neeg mob uas muaj GIST mob siab dua li imatinib thiab / lossis sunitinib raws li cov ntaub ntawv theem II thiab theem III, nws tsis tau tshuaj xyuas txoj hauv kev muaj txheej txheem hauv cov neeg mob uas muaj lwm hom sarcoma. Muab cov kev ua ntawm sorafenib, sunitinib thiab pazopanib hauv cov nqaij mos sarcomas, thiab cov pov thawj ntawm kev ua ntawm sorafenib hauv osteogenic sarcoma thiab tejzaum nws yog Ewing / Ewing-zoo li sarcoma, muaj qhov ua ntej los tshuaj xyuas SMOKIs (me me qauv ntawm lub qhov ncauj kinase inhibitors) xws li regorafenib hauv sarcomas lwm yam tshaj li GIST. Nws tseem lees paub tias SMOKIs (cov roj me me ntawm lub qhov ncauj kinase inhibitors) xws li regorafenib, sorafenib, pazopanib, thiab sunitinib muaj kev sib tshooj ntawm kinases uas muaj kev cuam tshuam ib txhij. Thaum tsis zoo sib xws,
Qhov chaw: 10 thaj chaw
Kev Nyab Xeeb, Kev Ncaj Ncees thiab Pharmacokinetics ntawm Anti-PD-1 Monoclonal Antibody hauv Cov Ntsiab Lus Nrog Advanced Malignancies
The primary objective is to assess the safety and tolerability of Toripalimab in subjects with various advanced malignancies and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of Toripalimab, 2) evaluate antitumor activity of Toripalimab; 3) determine the immunogenicity of Toripalimab; 4) evaluate overall survival. The exploratory objectives are to: 1) evaluate biomarkers that may correlate with activity of Toripalimab, 2) evaluate pharmacodynamic effects of Toripalimab on its target receptor, programmed cell death 1 (PD-1), as well as effects on the immune system. 3) evaluate the utility of PD-L1 & additional exploratory markers as biomarkers that could aid in selection of appropriate subjects for TAB001 therapy, and 4) identification of additional biomarkers correlating with response to treatment with TAB001.
Qhov chaw: 9 thaj chaw
